COMMUNIQUÉS West-GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2026
28/09/2026
Aggregated presentation by day and by market Weekly report on share repurchases from 21st September to 22nd September 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 39 - 2026
28/09/2026
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 21 septembre au 22 septembre 2026 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la [...]
Maxim Hair Restoration Named Best Hair Transplant Center at the 2026 Arte of Beauty Awards
28/09/2026
New York–founded hair restoration leader honored among hundreds of entries from 30+ countries New York City, NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Maxim Hair Restoration , a 15-location organization that operates [...]
Guerbet : Résultats semestriels 2026.
28/09/2026
Résultats semestriels 2026 Chiffre d’affaires de 379,2 M€, quasiment stable (-0,1%) à TCC 1 et périmètre comparable 2 , en ligne avec les anticipations du Groupe sur l’ensemble de l’exercice EBITDA à 30,6 M€ en ligne [...]
Guerbet : H1 2026 Results.
28/09/2026
H1 2026 Results Revenue of €379.2m, nearly stable (-0.1%) at CER 1 and like-for-like 2 , in line with the Group’s forecast for the full year EBITDA of €30.6m, in line with the Group’s forecast for the full year Restated [...]
Advance OC’s 2026 ‘Future of Healthcare Conference’ Returns to Irvine on October 7 at Major Inflection Point in U.S. Healthcare
28/09/2026
Dr. Sachin Jain of SCAN to keynote annual summit hosted at the UCI Beall Center for Innovation which will convene clinicians, policymakers, and community leaders to reimagine care across the lifespan IRVINE, Calif., [...]
PerfectServe Doubles Down on Innovation to Help Health Systems Define, Measure, and Achieve Operational Excellence
28/09/2026
Building on 30 years of healthcare operational experience, PerfectServe is investing in technologies that deliver immediate value while creating the foundation for connected operational intelligence. Summary Defining [...]
Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)
28/09/2026
Company announcement No. 50 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 39, 2026) Copenhagen, Denmark, September 28, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq [...]
Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026
28/09/2026
SEATTLE and VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and [...]
Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers
28/09/2026
Translational research demonstrates that SIL204 utilizes native serum lipids to facilitate intracellular delivery and robust KRAS oncogene knockdown Findings validate that physiological lipoprotein levels are sufficient [...]
Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection
28/09/2026
New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection DARE-HPV Phase 2 study underway with topline results expected [...]
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
28/09/2026
- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib - New proteomics and cell line capabilities will broaden Allarity’s research capabilities to enable external partnerships [...]
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
28/09/2026
DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, [...]
Curonix Announces Published PNS IMPACT Clinical Study Showing Freedom® Peripheral Nerve Stimulator (PNS) System is Associated with Reductions in Pain Scores, Opioid Use and Overall Patient Burden
28/09/2026
POMPANO BEACH, Fla., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Curonix LLC, a leading medical technology company dedicated to relieving chronic pain, today announced the publication of a milestone study, Peripheral Nerve [...]
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
28/09/2026
Initial data expected in the first half of 2027 LEXINGTON, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing [...]
Route 92 Medical Announces U.S. FDA Clearance for the FreeClimb® 46 Catheter with Tenzing® 4
28/09/2026
Expands Company’s Portfolio of Advanced Neurovascular Catheters to Support Treatment in Smaller and More Distal Anatomies WEST JORDAN, Utah, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held [...]
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
28/09/2026
4D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet need First patients have been enrolled in 4SIGHT global Phase 3 trial (N=514) evaluating [...]
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
28/09/2026
Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2- [...]
GuideAI Health Corp. and vRad Renew Data Exclusivity Agreement to Develop AI Models for the Detection and Characterization of Multiple Vascular Diseases
28/09/2026
Company holds exclusive access to imaging data from 2,100+ U.S. hospitals through its ongoing data partnership with vRad, the largest teleradiology provider in the United States BOSTON, Sept. 28, 2026 (GLOBE NEWSWIRE [...]

Pages